Allogene Therapeutics inc (ALLO)
Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
Industry • Biotechnology & Pharmaceuticals |
Sector • Healthcare |
News
Allogene Therapeutics Shows Promise with ALLO-647 Safety Data Amid Falling Revenues
Allogene Therapeutics Inc: Revolutionizing Autoimmune Disease Treatment with AlloCAR T Platform
The company reported it had very pressing period, over the second quarter of 2023 earnings season
Deficit on Weak Sales in the financial time-frame closing March 31 2023
The Losses have widen more due to Decrease in business in the October to December 31 2022 time-frame
Uninspiring performance by the company during the fiscal interval closing Sep 30 2022